SCHEMBL3793786

SCHEMBL3793786

CNc1cccc(N)c1-c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.43
TDP1 Q9NUW8 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
MAPK1 P28482 2/20 0.43
RAB9A P51151 2/20 0.43
EGFR P00533 1/20 0.43
PABPC1 P11940 1/20 0.43
ALDH1A1 P00352 4/20 0.42
KDM4E B2RXH2 4/20 0.42
HSD17B10 Q99714 3/20 0.42
USP2 O75604 1/20 0.42
POLB P06746 1/20 0.42
HPGD P15428 1/20 0.42
RECQL P46063 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
GAA P10253 3/20 0.41
LMNA P02545 2/20 0.41
KMT2A Q03164 2/20 0.41
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3789831 0.86 MAPT (0.41) MAPTTDP1SMN1; SMN2L3MBTL1MAPK1
SCHEMBL31570417 0.85 MAPT (0.50) MAPTTDP1SMN1; SMN2L3MBTL1MAPK1
SCHEMBL3791002 0.83 MAP4K4 (0.47) MAPTTDP1SMN1; SMN2L3MBTL1MAPK1
SCHEMBL3793482 0.80 MAPT (0.52) MAPTTDP1SMN1; SMN2L3MBTL1MAPK1
SCHEMBL27647090 0.78 MAPT (0.64) MAPTTDP1SMN1; SMN2L3MBTL1MAPK1
SCHEMBL21620393 0.78 MAPT (0.56) MAPTTDP1SMN1; SMN2L3MBTL1MAPK1
SCHEMBL5754263 0.78 ALDH1A1 (0.55) MAPTTDP1SMN1; SMN2L3MBTL1MAPK1
SCHEMBL11041638 0.78 MAPT (0.44) MAPTTDP1SMN1; SMN2L3MBTL1MAPK1
SCHEMBL30259184 0.77 IDO1 (0.39) MAPTL3MBTL1ALDH1A1KDM4EHSD17B10
SCHEMBL29920377 0.76 MAPT (0.43) MAPTTDP1SMN1; SMN2L3MBTL1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2010-04-08 US disclosed
EP-1914221-A1 PROCESS FOR PRODUCING BIARYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-04-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND NISCH, BLVRB, BBOX1 MAPT 3312/4885TDP1 4196/4885SMN1; SMN2 4524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.